The funding round was led by BGF and Scottish National Investment Bank (The Bank), with additional support from existing investor Scottish Enterprise. The multi-million-pound investment will enable Aberdeen-based Elasmogen to continue developing its pipeline of next-generation drugs through pre-clinical trials. The company’s soloMERTM technology is based on molecules naturally found in sharks’ immune systems, which are the equivalent of human antibodies but smaller and more stable.